The treatment of alcohol and opioid dependence in pregnant women

Current Opinion in Psychiatry

Volumn 25, Issue 6, 2012, Pages 559-564

  Heberlein, Annemarie ^a   Leggio, Lorenzo ^b   Stichtenoth, Dirk ^a   Hillemacher, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BROWN UNIVERSITY   (United States)

Author keywords

Alcohol dependence; Childbearing; Opioid dependence; Opioid maintenance treatment; Pregnancy

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; CLOMETHIAZOLE; DIAMORPHINE; METHADONE; MORPHINE;

ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; COGNITIVE DEFECT; DETOXIFICATION; DISEASE ASSOCIATION; FETUS DISEASE; FIRST TRIMESTER PREGNANCY; HUMAN; OPIATE ADDICTION; PREGNANT WOMAN; PRENATAL EXPOSURE; REVIEW;

ALCOHOLISM; FEMALE; HUMANS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84867293718     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328358ad36     Document Type: Review

References (82)

1. Wallace C, Burns L, Gilmour S, Hutchinson D. Substance use, psychological distress and violence among pregnant and breastfeeding Australian women. Aust N Z J Public Health 2007; 31:51 -56. (Pubitemid 46380634)
2. Lobmaier P, Gossop M, Waal H, Bramness J. The pharmacological treatment of opioid addiction - a clinical perspective. Eur J Clin Pharmacol 2010; 66:537-545.
3. Gyarmathy VA, Giraudon I, Hedrich D, et al. Drug use and pregnancy: challenges for public health. Euro Surveill 2009; 14:33-36.
4. Florey CD. EUROMAC A European concerted action: maternal alcohol consumption and its relation to the outcome of pregnancy and child devel-opment at 18 months. Methods Int J Epidemiol 1992; 21 (Suppl. 1):S38-S39.
5. Mactier H.The management of heroin misuse in pregnancy: time for are think? Arch Dis Child Fetal Neonatal Ed 2011; 96:F457-F460.
6. Burd L, Martsolf JT. Fetal alcohol syndrome: diagnosis and syndromal variability. Physiol Behav 1989; 46:39-43. (Pubitemid 19213948)
7. Walloch JE, Burger PH, Kornhuber J. [What is known about the outcome as adults for children with fetal alcohol syndrome (FAS)/fetal alcohol spectrum disorders (FASD)?] (in German). Fortschr Neurol Psychiatr 2012; 80:320-326.
8. Landgren M, Svensson L, Stromland K, Andersson Gronlund M. Prenatal alcohol exposure and neurodevelopmental disorders in children adopted from eastern Europe. Pediatrics 2010; 125:e1178-e1185.
9. O'Leary CM. Fetal alcohol syndrome: diagnosis, epidemiology, and develop-mental outcomes. J Paediatr Child Health 2004; 40:2-7. (Pubitemid 38333585)
10. O'Leary CM, Watson L, D'Antoine H, etal. Heavy maternal alcohol consump-tion andcerebral palsyintheoffspring. Dev Med Child Neurol 2012; 54:224-230.
11. Alvik A, Heyerdahl S, Haldorsen T, Lindemann R. Alcohol use before and during pregnancy: a population-based study. Acta Obstet Gynecol Scand 2006; 85:1292-1298. (Pubitemid 44601035)
12. Patra J, Bakker R, Irving H, et al. Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birthweight, preterm birth and small for gestational age (SGA) - a systematic review and meta-analyses. BJOG 2011; 118:1411-1421.
13. Henderson J, Gray R, Brocklehurst P. Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome. BJOG 2007; 114:243-252.
14. Bay B, Kesmodel US. Prenatal alcohol exposure - a systematic review of the effects on child motor function.Acta Obstet Gynecol Scand 2010; 90:210-226.
15. Todorow M, Moore TE, Koren G. Investigating the effects of lowto moderate levels of prenatal alcohol exposure on child behaviour: a critical review. J Popul Ther Clin Pharmacol 2010; 17:e323-e330.
16. O'Leary C, Zubrick SR, Taylor CL, et al. Prenatal alcohol exposure and language delay in 2-year-old children: the importance of dose and timing on risk. Pediatrics 2009; 123:547-554.
17. O'Leary CM, Nassar N, Zubrick SR, etal. Evidence of a complex association between dose, pattern and timing of prenatal alcohol exposure and child behaviour problems. Addiction 2010; 105:74-86.
18. Sokol RJ, Martier SS, Ager JW. The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol 1989; 160:863-868; discussion 868-870.
19. Chang G,Wilkins-Haug L, Berman S,Goetz MA.The TWEAK:application in a prenatal setting. J Stud Alcohol 1999; 60:306-309.
20. Russell M, Martier SS, Sokol RJ, etal. Screening for pregnancy risk-drinking. Alcohol Clin Exp Res 1994; 18:1156-1161. (Pubitemid 24345523)
21. Sarkar M, Einarson T, Koren G. Comparing the effectiveness of TWEAK and T-ACE in determining problem drinkers in pregnancy. Alcohol Alcohol 2010; 45:356-360.
22. Burns E, Gray R, Smith LA. Briefscreening questionnairesto identify problem drinking during pregnancy: a systematic review. Addiction 2010; 105:601 -614.
23. Chang G, Goetz MA, Wilkins-Haug L, Berman S. Identifying prenatal alcohol use: screening instruments versus clinical predictors. Am J Addict 1999; 8:87-93. (Pubitemid 29242233)
24. Bradley KA, Boyd-Wickizer J, Powell SH, Burman ML Alcohol screening questionnaires in women: a critical review. JAMA 1998; 280:166-171. (Pubitemid 28498390)
25. Russell M, Martier SS, Sokol RJ, et al. Detecting risk drinking during preg-nancy: a comparison of four screening questionnaires. Am J Public Health 1996; 86:1435-1439. (Pubitemid 26346605)
26. Wurst FM, Kelso E, Weinmann W, et al. Measurement of direct ethanol metabolites suggests higher rate of alcohol use among pregnant women than foundwith the AUDIT - apilotstudy in apopulation-based sampleof Swedish women. Am J Obstet Gynecol 2008; 198:407 e1 -407 e5.
27. Cook JD. Biochemical markers of alcohol use in pregnant women. Clin Biochem 2003; 36:9-19. (Pubitemid 36126385)
28. Bianchi V, Ivaldi A, Raspagni A, et al. Pregnancy and variations of carbohy-drate-deficient transferrin levels measured by the candidate reference HPLC method. Alcohol Alcohol 2011; 46:123-127.
29. Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally adminis-tered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol 2008; 6:125-150. (Pubitemid 352024797)
30. Sanchez ES, Bigbee JW, Fobbs W, et al. Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain. Glia 2008; 56:1017-1027.
31. Barone R, Walrand S, Konijnenberg M, et al. Therapy using labelled soma-tostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nucl Med Commun 2008; 29:283-290.
32. Todd RD. Neural development is regulated by classical neurotransmitters: dopamine D2 receptor stimulation enhances neurite outgrowth. Biol Psychia-try 1992; 31:794-807.
33. Rosen TS, Johnson HL. Children of methadone-maintained mothers: follow-upto18 months of age. J Pediatr 1982; 101:192-196. (Pubitemid 12098765)
34. Walhovd KB, Moe V, Slinning K, et al. Volumetric cerebral characteristics of children exposed to opiates and other substances in utero. Neuroimage 2007; 36:1331 -1344. (Pubitemid 47001728)
35. Zagon IS, Mc Laughlin PJ. Behavioral effects of prenatal exposure to opiates. Monogr Neural Sci 1983; 9:159-168.
36. Zagon IS, Mc Laughlin PJ. The effects of different schedules of methadone treatment on rat brain development. Exp Neurol 1977; 56:538-552. (Pubitemid 8171441)
37. Nagy Z, Westerberg H, Klingberg T. Maturation ofwhite matter is associated with the development of cognitive functions during childhood. J Cogn Neurosci 2004; 16:1227-1233. (Pubitemid 39274449)
38. Dawe S, Harnett PH, Staiger P, Dadds MR. Parent training skills and methadone maintenance: clinical opportunities and challenges. Drug Alcohol Depend 2000; 60:1-11. (Pubitemid 30255980)
39. Brown CG, Stewart SH, Larsen SE. Experiences of harm reduction among women with alcohol use problems. Can J Commun Ment Health 2005; 24:95-113. (Pubitemid 43151438)
40. Marlatt GA, Witkiewitz K. Harm reduction approaches to alcohol use: health promotion, prevention, and treatment. Addict Behav 2002; 27:867-886. (Pubitemid 36158753)
41. Kinsella MT, Monk C. Impact of maternal stress, depression and anxiety on fetal neurobehavioral development.Clin Obstet Gynecol 2009; 52:425-440.
42. Diego MA, Jones NA, Field T, etal. Maternal psychological distress, prenatal cortisol, and fetal weight. Psychosom Med 2006; 68:747-753. (Pubitemid 44454644)
43. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol with-drawal. Cochrane Database Syst Rev 2010; (3):CD005063.
44. Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological inter-ventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev 2011; (6):CD008537.
45. Iqbal MM, Sobhan T, Aftab SR, Mahmud SZ. Diazepam use during pregnancy: a review of the literature. Del Med J 2002; 74:127-135.
46. Safra MJ, Oakley GP Jr. Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet 1975; 2:478-480.
47. Rosenberg L, Mitchell AA, Parsells JL, et al. Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 1983; 309:1282-1285. (Pubitemid 14201583)
48. Dolovich LR,Addis A,Vaillancourt JM, etal. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998; 317:839-843. (Pubitemid 28434551)
49. Marinucci L, Balloni S, Carinci F, et al. Diazepam effects on nonsyndromic cleftlipwith orwithoutpalate:epidemiologicalstudies, clinicalfindings,genes and extracellular matrix. Expert Opin Drug Saf 2011; 10:23-33.
50. Mc Elhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994; 8:461 -475.
51. Herran A, Vazquez-Barquero JL. Treating alcohol dependence. Chlormethia-zole iswidely used in Europe. BMJ 1997; 315:1466.
52. Jentink J, Dolk H, Loane MA, etal. Intrauter in eexposuret ocarbamazepine and specificcongenital malformations:systematic reviewand case-control study. BMJ 2010; 341:c6581.
53. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010; 362:2185-2193.
54. Chang G, Mc Namara TK, Orav EJ, et al. Brief intervention for prenatal alcohol use: a randomized trial. Obstet Gynecol 2005; 105(5Pt 1):991 -998. (Pubitemid 40571016)
55. Nilsen P. Brief alcohol intervention to prevent drinking during pregnancy: an overview of research findings. Curr Opin Obstet Gynecol 2009; 21:496-500.
56. O'Connor MJ, Whaley SE. Brief intervention for alcohol use by pregnant women. Am J Public Health 2007; 97:252-258. (Pubitemid 47279371)
57. Chang G, Wilkins-Haug L, Berman S, Goetz MA. Brief intervention for alcohol use in pregnancy: a randomized trial. Addiction 1999; 94:1499-1508. (Pubitemid 29481580)
58. Stade BC, Bailey C, Dzendoletas D, et al. Psychological and/or educational interventionsforreducing alcoholconsumption in pregnantwomenand women planning pregnancy. Cochrane Database Syst Rev 2009; (2):CD004228.
59. Blanc M, Daeppen JB. [Does disulfiram still have a role in alcoholism treatment?] (in French). Rev Med Suisse 2005; 1:1728-1730; 1732-1733.
60. Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des 2010; 16:2091 -2097.
61. Mann K. Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs 2004; 18:485-504. (Pubitemid 38829945)
62. Johnson BA, Ait-Daoud N.Topiramate in the newgeneration of drugs: efficacy in the treatment of alcoholic patients.Curr Pharm Des 2010; 16:2103-2112.
63. Leggio L, Garbutt JC, Addolorato G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets 2010; 9:33-44.
64. Kenna GA. Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Curr Pharm Des 2010; 16:2126-2135.
65. Jones HE. Acceptance of naltrexone by pregnant women enrolled in com-prehensive drug addiction treatment: an initial survey. Am J Addict 2012; 21:199-201.
66. Farid WO, Mc Callum D, Tait RJ, etal. Minor pathological changes are induced by naltrexone-poly(DL-lactide) implantsin pregnant rats.J Biomed Mater Res A 2009; 91:964-974.
67. Hulse GK, O'Neil G, Arnold-Reed DE. Methadone maintenance vs. implan-table naltrexone treatment in the pregnant heroin user. Int J Gynaecol Obstet 2004; 85:170-171. (Pubitemid 38510235)
68. Hulse G, O'Neil G. Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol 2002; 42:569-573. (Pubitemid 35385713)
69. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2003; 24:363-367. (Pubitemid 36809290)
70. Mc Carthy JJ. Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? J Matern Fetal Neonatal Med 2012; 25:109-112.
71. Winklbaur B, Jung E, Fischer G. Opioid dependence and pregnancy. Curr Opin Psychiatry 2008; 21:255-259. (Pubitemid 351489345)
72. Wong S, Ordean A, Kahan M. Substance use in pregnancy. J Obstet Gynaecol Can 2011; 33:367-384.
73. Fischer G, Ortner R, Rohrmeister K, et al. Methad oneversus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addic-tion 2006; 101:275-281. (Pubitemid 43351601)
74. Jones HE, Johnson RE,Jasinski DR, etal. Buprenorphineversus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79:1-10. (Pubitemid 41557119)
75. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Prospective multi-center observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82:250-257.
76. Fajemirokun-Odudeyi O, Sinha C, Tutty S, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006; 126:170-175.
77. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinicaland research issues.JSubst Abuse Treat2008;35:245-259.
78. Unger AS, Martin PR, Kaltenbach K, et al. Clinical characteristics of central European and North American samples of pregnant women screened for opioid agonisttreatment. Eur Addict Res 16:99-107.
79. Stine SM, Heil SH, Kaltenbach K, et al. Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screen-ing results from the MOTHER study. Am J Drug Alcohol Abuse 2009; 35:429-433.
80. Minozzi S, Amato L, Vecchi S, Davoli M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008; (2):CD006318.
81. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during preg-nancy. Effects and management. Obstet Gynecol Clin North Am 1998; 25:139-151. (Pubitemid 28141705)
82. Hartwig C, Haasen C, Reimer J, etal. Pregnancy and birth undermaintenance treatment with diamorphine (heroin): a case report. Eur Addict Res 2008; 14:113-114. (Pubitemid 351365644)